BALPHARMA · NSE
Bal Pharma Limited
₹108.28
+0.11% (+₹0.12)
Prev. close
₹108.16
Volume
36,829
Delivery %
45.8%
As of
23 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Shailesh Dheerajmal Siroya
Headquarters
Bengaluru
Employees
939
Website
balpharma.comExchange
View on NSE ↗Key stats
Market cap
₹172.39 Cr
P/E ratio (TTM)
23.9
Dividend yield
1.11%
EPS (TTM)
₹4.53
Beta (1Y · daily vs NIFTY 50)
0.90
Beta (5Y · monthly vs NIFTY 50)
1.18
Shares float
54.24 L
EPS · quarter ended Jun 2026
₹0.71
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.8% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹250.53 Cr | ₹281.21 Cr | ₹304.22 Cr | ₹339.22 Cr | ₹303.08 Cr | ₹311.66 Cr | |
| EBITDA | ₹25.60 Cr | ₹28.63 Cr | ₹24.37 Cr | ₹33.60 Cr | ₹29.45 Cr | ₹31.90 Cr |
| ₹4.74 Cr | ₹5.61 Cr | ₹2.57 Cr | ₹7.39 Cr | ₹7.22 Cr | ₹6.28 Cr | |
| Diluted EPS | ₹3.34 | ₹3.71 | ₹1.68 | ₹4.96 | ₹4.56 | ₹3.95 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹240.00 Cr | ₹261.00 Cr | ₹311.00 Cr | ₹320.00 Cr | ₹336.00 Cr | ₹376.00 Cr | |
| — | — | ₹133.08 Cr | ₹142.25 Cr | ₹150.41 Cr | ₹166.61 Cr | |
| Stockholders' equity | ₹54.00 Cr | ₹59.00 Cr | ₹64.00 Cr | ₹72.00 Cr | ₹78.00 Cr | ₹82.00 Cr |
CWIP, Others, Total debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹22.21 Cr | ₹32.05 Cr | ₹-1.54 Cr | ₹22.81 Cr | ₹20.32 Cr | ₹30.84 Cr | |
| Investing cash flow | ₹0 | ₹11.34 Cr | ₹-22.18 Cr | ₹-18.89 Cr | ₹-14.92 Cr | ₹-20.70 Cr |
| ₹-32.27 Cr | ₹1.11 Cr | ₹24.09 Cr | ₹-1.21 Cr | ₹-7.84 Cr | ₹-9.59 Cr | |
| Capital expenditure | ₹0 | ₹0 | ₹-14.65 Cr | ₹-10.98 Cr | ₹-18.79 Cr | ₹-22.38 Cr |
| End cash position | — | — | ₹1.49 Cr | ₹4.20 Cr | ₹1.75 Cr | ₹2.30 Cr |
Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Mar 22(2Q) | Apr 22–Sep 22(3Q) | Dec 22–Sep 23(4Q) | Dec 23–Jun 24(3Q) | Sep 24–Jun 26(8Q) |
|---|---|---|---|---|---|---|
| Promoter | 46.87% | 49.57% | 52.00% | 51.61% | 51.23% | 50.86% |
| Public | 53.13% | 50.43% | 48.00% | 48.39% | 48.77% | 49.14% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Bal Pharma Limited | ₹172.39 Cr | ₹108.28 | 23.9 | 2.10 | 7.6% | 2.03 | +3.0% | +28.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Bal Pharma Share Price update after 9.70% gain to Rs 110
Bal Pharma Ltd. shares rose 9.7% to Rs 110, closing at its daily high. The company's market capitalization stands at Rs 159.64 crore. No specific company-related catalyst for the price increase was identified.
Bal Pharma Limited (NSE:BALPHARMA) Looks Interesting, And It's About To Pay A Dividend
simplywall.st · 11 days ago